Poolbeg Pharma (LON:POLB) Trading Up 17.3%

Poolbeg Pharma PLC (LON:POLB) was up 17.3% on Tuesday . The company traded as high as GBX 15.77 ($0.20) and last traded at GBX 15.70 ($0.20). Approximately 8,653,346 shares traded hands during mid-day trading, an increase of 291% from the average daily volume of 2,212,504 shares. The stock had previously closed at GBX 13.39 ($0.17).

Poolbeg Pharma Price Performance

The company has a market cap of £68 million, a price-to-earnings ratio of -1,360.00 and a beta of 2.27. The company’s 50-day simple moving average is GBX 10.41 and its 200-day simple moving average is GBX 9.45.

Insider Activity

In other Poolbeg Pharma news, insider Jeremy Skillington bought 154,764 shares of the stock in a transaction dated Wednesday, February 21st. The stock was bought at an average cost of GBX 11 ($0.14) per share, for a total transaction of £17,024.04 ($21,386.98). In related news, insider Cathal Friel purchased 830,000 shares of the business’s stock in a transaction that occurred on Monday, February 19th. The shares were purchased at an average cost of GBX 12 ($0.15) per share, with a total value of £99,600 ($125,125.63). Also, insider Jeremy Skillington acquired 154,764 shares of the firm’s stock in a transaction on Wednesday, February 21st. The shares were bought at an average cost of GBX 11 ($0.14) per share, with a total value of £17,024.04 ($21,386.98). Insiders own 21.50% of the company’s stock.

About Poolbeg Pharma

Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.